Read Taconic's response to coronavirus (COVID-19), and visit our toolkit for researchers. Learn More

hIL-15 NOG

hIL-15 NOG Mouse Model
Order This Model OR Request a Quote
CALL: 888.822.6642 + 45 70 23 04 05 (EUROPE)

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • 13683-F
    sp/sp;ko/ko;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL2/IL15)1-1Jic/JicTac
  • 13683-M
    sp/sp;ko/y;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL2/IL15)1-1Jic/JicTac

  • Super immunodeficient NOG mouse expressing human IL-15 cytokine
  • Predominant differentiation of human NK cells following human HSC engraftment compared to the base NOG mouse, but survival time is limited
  • Human NK cells developed in hIL-15 NOG mice following HSC engraftment express various NK receptors and produce both granzyme A and perforin upon stimulation
  • Engraftment and expansion of human NK cells following engraftment with CD56+ NK cells derived from PBMCs
  • May be useful for efficacy studies involving antibody therapeutics with antibody dependent cell cytotoxcity mechanism of action
  • Applications in research involving cancer, infectious disease, immunology, regenerative medicine and human immune system engraftment
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
What our customers say:

“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”
Experimental Pharmacology & Oncology (EPO) GmbH

taconic biosciences' webinarWatch the Related Taconic Biosciences' Webinar:

Origin:

The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The hIL-15 NOG mouse was developed by microinjecting a transgene consisting of a DNA fragment containing human IL-15 cDNA with a hIL-2 signal peptide, under the control of a CMV-promoter, into zygotes of NOD/ShiJic-Il2rg mice.  Founders were backcrossed to NOG mice to establish the hIL-15 NOG line. Taconic received stock in 2014, and the line was derived through embryo transfer.

Availability:

Available now*
*Please note that advance order is encouraged for order of male mice. There is a minimal 4-week advance notice required on orders of male older than 3 weeks of age.

Color:

Albino

Species:

Mouse

Initial Publication:

Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γnull/c mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.
Fukuchi Y, Miyakawa Y, Kobayashi K, Kuramochi T, Shimamura K, Tamaoki N, Nomura T, Ueyama Y, Ito M. (1998) Cytokine dependent growth of human TF-1 leukemic cell line in human GM-CSF and IL-3 producing transgenic SCID mice. Leuk Res 22(9):837-43.

*The hIL-15 NOG mouse has not been published yet. Initial publications above refer to the core NOG mouse.


Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

Does your research require the use of neonates? Please contact us for more information on neonate access options.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

Human NK-Cells Engraft in hIL-15 NOG Mice

Distribution of long-term engrafting human NK cells in hIL-15 transgenic NOG mice

Distribution of long-term engrafting human NK cells in hIL-15 transgenic NOG
Figure 1: (a) Expansion of transferred human NK cells in NOG mice expressing human IL-15. X-irradiated NOG and hIL-15 NOG mice received human NK cells from peripheral blood magnetic cell sorting. Blood was collected and analyzed by FACS every week for 24 weeks after transfer. The absolute numbers of human NK cells in mouse peripheral blood are shown. (n = 6 for NOG and hIL-15 NOG mice). (b) Means +/- SD of the human NK-cell frequencies in each tissue are shown (n = 6). (c) Frequencies of CD56dimCD16+ and CD56hiCD16− subpopulations in total CD56+ NK cells are shown (n = 6 for bone marrow (BM), spleen, and PB; n = 3 for liver and lung). Adapted from Katano, et al. 2018 under Creative Commons Attribution License.

Human NK cells expand in hIL-15 NOG engrafted with human PBMCs

Human NK cells expand in hIL-15 NOG engrafted with human PBMCs
Figure 2: Human immune cell engraftment in hIL-15 NOG vs NOG mice. Data from peripheral blood analysis of human T cells (a), B cells (b), NK cells (c), and monocytes (d), performed at 18, 25, and 32 days post PBMC engraftment. Single donor's cells were engrafted into both models at the indicated cell dose. Adapted from Volden, et al. 2018.

Anti-tumor ADCC with NK-cell Humanized hIL-15 NOG Mice

In vivo antibody-dependent cell-mediated cytotoxicity (ADCC) activity human NK-cell engrafted hIL-15 transgenic NOG

In vivo antibody-dependent cell-mediated cytotoxicity (ADCC) activity human NK-cell engrafted hIL-15 transgenic NOG
Figure 3: (a) Tumor suppression by in vitro-expanded human peripheral blood NK cells and anti-Her2 treatment. Her2-positive NCI-N87 cells, a gastric-cancer cell line, were inoculated into X-irradiated hIL-15 NOG mice. Human peripheral blood NK cells, expanded in vitro, were transplanted with or without anti-Her2 antibody. (b) Tumor suppression by in vitro-expanded human NK cells and anti-CCR4 treatment. X-irradiated hIL-15 NOG mice were subsequently inoculated with L428 Hodgkin lymphoma cells. In vitro-expanded human peripheral blood NK cells were transplanted 1 week after tumor inoculation and administration of anti-CCR4 antibody or control antibody was started. Adapted from Katano, et al. 2018 under Creative Commons Attribution License.

Human NK-cell engrafted hIL-15 NOG as a model for antibody-mediated NK cell depletion and ADCC

Human NK-cell engrafted hIL-15 NOG as a model for antibody-mediated NK cell depletion and ADCC
Figure 4: (a) Experimental timeline and (b) study groups. (c) Dynamics of absolute NK cell numbers per microliter of blood over the course of the study. (d) NK cell staining with viability dye Zombie Violet. (e) Raji tumor growth kinetics and CD69 activation marker on peripheral blood (f) and tumor infiltrating (g) human NK cells. Adapted from Bunin, et al. 2019.
hIL-15 expression levels: A cohort of 12 female and 10 male hIL-15 NOG mice were assayed for hIL-15 levels in serum via Luminex assay. hIL-15 levels in serum were in the range of ~150-250 pg/mL.